首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1542928

全球 HDL 膽固醇試劑盒市場 - 2024-2031

Global HDL Cholesterol Kits Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

2023年，全球HDL膽固醇試劑盒市場規模達到6.4702億美元，預計2031年將達到10.0568億美元，2024-2031年預測期間複合年成長率為5.8%。

血漿脂蛋白包括許多主要類型，其中之一是高密度脂蛋白（HDL）。它們的大小、脂質和載脂蛋白含量各不相同，由許多異質顆粒組成，包括膽固醇。高密度脂蛋白負責將膽固醇從周邊細胞轉移到肝臟，在那裡轉化為膽汁酸並透過腸道消除。

HDL-C 的精確評估對於確定患者罹患冠心病的風險至關重要。當使用直接測量代替沉澱技術時，準確性和可重複性會提高。通常，高密度脂蛋白與其他測試一起進行，例如膽固醇或血脂譜（包括三酸甘油酯和低密度脂蛋白）的測試。高密度脂蛋白和總膽固醇一起是心臟病風險非常有用的篩檢工具。

市場動態：

司機

心血管疾病盛行率上升

隨著全球人口特別是老年人口的成長，中風、動脈粥狀硬化、冠狀動脈疾病和心臟病等心血管疾病的發生率預計也會上升，對醫療干預產生巨大的需求。根據聯合國統計，到2030年，全球人口預計將達到85億，2050年將達97億。根據世界衛生組織（WHO）估計，2030年60歲以上老年人口將接近14億，2050年將達21億。

大多數心血管疾病的罪魁禍首是低密度脂蛋白（LDL）、極低密度脂蛋白（VLDL）、三酸甘油酯和膽固醇。這些物質的累積會導致身體各部位的血液循環受阻，進而導致嚴重的疾病。高密度脂蛋白（HDL），也稱為好膽固醇，已知可以降低壞膽固醇的水平，尤其是低密度脂蛋白。這種高密度脂蛋白有助於分解在血管中形成血栓的低密度脂蛋白，並將其運回肝臟，低密度脂蛋白在肝臟中被隔離並從體內消除或以脂質細胞的形式儲存。

HDL-C 測試是為了評估患者的心血管健康狀況，包括心臟病的風險。好膽固醇（HDL-C）與降低冠心病事件的風險有關。醫生可以透過測量相同血液樣本中的總膽固醇和 HDL-C 輕鬆計算 HDL-C 與非 HDL 膽固醇的比率，這對於評估患者的心血管健康至關重要。

現代世界人口老化、久坐的生活方式和飲食習慣的改變預計將增加心血管疾病的發病風險。

例如，美國心臟協會指出，全球約有 1,800 萬人死於心血管疾病 (CVD)，高收入國家和低收入國家 (HIC) 以及中低收入國家之間存在顯著差異。中低收入國家在全球心血管疾病 (CVD) 負擔中所佔比例過高，佔全球所有心血管疾病死亡人數的 80%。

此外，根據澳洲國家心臟基金會的數據，六分之一的澳洲人患有心血管疾病，病例數接近 450 萬，佔澳洲總人口的 18%。此外，澳洲有超過 1500 例住院病例和 24% 的死亡病例是由 CVD 造成的。

隨著這一趨勢預計將上升，對預防性健康措施的需求預計將增加，其中包括及時的心臟健康監測，預計將在預測期內對高密度脂蛋白膽固醇檢測試劑盒產生巨大的需求。

限制

高密度脂蛋白膽固醇試劑盒的高成本是可能阻礙市場成長的限制因素之一。對於營運預算較低的小型衛生中心和診所來說，這可能是一種經濟負擔。此外，患者尤其是生活在農村地區的患者對定期膽固醇檢查的重要性缺乏認知是可能限制市場成長的另一個因素。

Market Overview

The Global HDL Cholesterol Kits Market reached US$ 647.02 million in 2023 and is expected to reach US$ 1,005.68 million by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.

Plasma lipoproteins include many primary types, one of which is high-density lipoproteins (HDL). They vary in size and lipid and apolipoprotein content and are made up of many heterogeneous particles, including cholesterol. HDL is responsible for transferring cholesterol from peripheral cells to the liver, where it is transformed into bile acids and eliminated through the intestines.

Precise evaluation of HDL-C is essential for determining a patient's risk of coronary heart disease. When direct measurement is used instead of precipitation techniques, accuracy and repeatability are increased. Typically, HDL is ordered in conjunction with additional tests, such as those for cholesterol or lipid profiles that include triglycerides and LDL. HDL and total cholesterol together are a highly helpful screening tool for heart disease risk.

Market Dynamics: Drivers

Rising prevalence of cardiovascular conditions

As the global population is rising especially the old-age demographic, the incidence of cardiovascular conditions such as stroke, atherosclerosis, coronary artery disease, and heart attack are also expected to rise, creating a huge demand for medical intervention. As per the United Nations statistics, by 2030, the global population is predicted to reach 8.5 billion and in 2050 to 9.7 billion. As per the World Health Organization (WHO) estimates, the old-age population above 60 years would be nearly 1.4 billion in 2030 and 2.1 billion in 2050.

The major culprit behind majority of the cardiovascular conditions is low-density lipoprotein (LDL), very low-density lipoproteins (VLDL), triglycerides, and cholesterol. Accumulation of these will lead to blockage of blood circulation to various parts of the body that results in serious morbid conditions. The high-density lipoprotein (HDL), also known as good cholesterol, is known to reduce the levels of bad cholesterol, especially LDL. This HDL helps to break down the LDL that forms thrombus in the blood vessels and transport it back to the liver, where the LDL is sequestered and eliminated from the body or stored in the form of lipid cells.

Testing for HDL-C is done to evaluate the patient's cardiovascular health, including their risk of heart disease. Good cholesterol, or HDL-C, is linked to a decreased risk of coronary heart disease events. The ratio of HDL-C to non-HDL cholesterol may be readily computed by the physician by measuring both total cholesterol and HDL-C in the same blood sample, which is vital for evaluating the patient's cardiovascular health.

The aging population demographic, sedentary lifestyle, and change in eating habits in the modern world are expected to increase the risk of cardiovascular disease incidence.

For instance, American Heart Association, Inc. states that around 18 million deaths globally are attributed to cardiovascular disease (CVD), with significant differences between high- and low-income countries (HICs) and LMICs. LMICs bear a disproportionate amount of the global burden of cardiovascular diseases (CVDs), accounting for 80% of all cardiovascular deaths globally.

In addition, as per the National Heart Foundation of Australia, one in six Australians is living with a cardiovascular disease accounting for nearly 4.5 million cases, which represent 18% of the total Australian population. In addition, more than 1500 hospital admissions and 24% of all deaths in Australia are attributed to CVD.

As this trend is expected to rise, the demand for preventative health measures is expected to rise that include timely heart health monitoring, is expected to create a huge demand for HDL cholesterol testing kits in the forecast period.

Restraints

The high cost of HDL cholesterol kits is one of the restraining factors that may hinder market growth. This can be an economic burden to small-scale health centers and clinics with low operational budgets. In addition, the lack of awareness among patients especially those living in rural areas regarding the importance of regular cholesterol checkups is another factor that may restrain the market growth.

Segment Analysis

The global HDL cholesterol kits market is segmented based on product type, modality, end-users, and region.

The colorimetry based kits in the type segment accounted for approximately 56.4% of the global HDL cholesterol kits market share

HDL cholesterol is routinely evaluated together with total cholesterol, LDL cholesterol, and triglycerides to track each patient's unique risk of developing cardiovascular disease. The most popular method for measuring HDL cholesterol is enzymatic colorimetric techniques, the gold standard for lipid analysis of this kind. Since the development of color is the endpoint in this process, the intensity, and other parameters can be estimated by employing ultraviolet-visible spectroscopy at 500 nm. This is a widely accepted method due to its simplicity, cost-effectiveness, sensitivity, and specificity. Moreover, many HDL detection kits manufactured by prominent players utilize the colorimetric method.

Geographical Analysis

North America is expected to dominate the market with a 43.2% share in the global HDL cholesterol kits market

North America is expected to dominate the market due to its well-advanced healthcare infrastructure, state-of-the-art diagnostic centers, clinical laboratories, etc. Moreover, the the major high-income countries in the region the U.S. and Canada are well-known for their investments in the healthcare industry

For instance, Laboratory Corporation of America Holdings has nearly 2,000 centers spanning across the U.S. providing several diagnostic testing services including the cholesterol panel. Quest Diagnostics, another prominent diagnostic service provider has over 2,000 of its patient service centers and nearly 7,400 patient access points in the U.S.

This well-established network of clinical laboratories provides testing services all across the nation making the service easily accessible by all the population.

Moreover, the region is known for its high prevalence of cardiovascular-related events. As per the American Heart Association's heart disease and stroke statistics 2024 update, nearly 222.4 per 100,000 patients age-adjusted death rate attributable to CVD, and nearly 25.5% of the U.S. adult population have their LDL-cholesterol greater than 130mg/dL. Low-density lipoprotein (LDL) is the major culprit in the majority of cardiovascular conditions such as ischemia, atherosclerosis, and stroke. Moreover, nearly 9.7 million people in the U.S. have undiagnosed diabetes, 29.3 million people have been diagnosed with diabetes and 115.9 million people are at risk of pre-diabetes.

Considering the high prevalence of cardiovascular indications, and the well-established healthcare systems combined with top-tier clinical laboratories providing HDL testing services the demand and the sales volume of HDL cholesterol kits is far higher in the North American region. In addition, most market leaders have established a stronghold market position in the region, making the kits easily available to healthcare facilities. All these factors are expected to be contributing to the region's dominance in the global market for HDL cholesterol kits.

Covid-19 Analysis

The Covid-19 pandemic had a significant impact on the market of HDL cholesterol kits. During the pandemic, the global supply chain has been disrupted due to imposed restrictions on movement and lockdowns. The restriction in movement has reduced the hospital and clinical laboratory visits by the patients, which is anticipated to have resulted in decreased HDL cholesterol testing volumes. Moreover, the clinical labs and hospitals were majorly focused on providing testing services to the Covid-infected patients which is anticipated to have resulted in decreased testing volume.

For instance, a study conducted in the Mass General Brigham (MGB) which is a large integrated healthcare system serving Massachusetts and its neighboring states, has found a 39.2% decline in weekly cholesterol tests from 6,361 in 2019 to 3,867 in 2020, with the greatest reductions occurring during the first wave of the pandemic accounting for 92% reduction in the testing volume.

Market Segmentation

By Type

Colorimetry Based Kits
Fluorometry Based Kits
Precipitation Based Kits
Others

By Sample Type

Serum
Plasma
Urine
Others

By End-Users

Hospitals
Specialty Clinics
Diagnostic Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
South America
- Brazil
- Argentina
- Rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Competitive Landscape

The major players in the HDL cholesterol kits market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Merck KGaA, Randox Laboratories Ltd., SEKISUI Diagnostics, Abcam Limited., Diazyme Laboratories, Inc., Cell Biolabs, Inc. and DiaSys Diagnostic Systems GmbH among others.

Why Purchase the Report?

To visualize the global HDL cholesterol kits market segmentation based on type, sample type, end-users and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of HDL cholesterol kits market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global HDL cholesterol kits market report would provide approximately 62 tables, 55 figures, and 187 Pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Sample Type
3.3. Snippet by End-Users

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising prevalence of cardiovascular conditions
  - 4.1.1.2. Rising technological advancements
- 4.1.2. Restraints
  - 4.1.2.1. Lack of awareness and limited access to healthcare
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Colorimetry Based Kits*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Fluorometry Based Kits
7.4. Precipitation Based Kits
7.5. Others

8. By Sample Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 8.1.2. Market Attractiveness Index, By Sample Type
8.2. Serum*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Plasma
8.4. Urine
8.5. Others

9. By End-Users

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 9.1.2. Market Attractiveness Index, By End-Users
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Diagnostic Centers
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.5.1. Germany
  - 10.3.5.2. UK
  - 10.3.5.3. France
  - 10.3.5.4. Italy
  - 10.3.5.5. Spain
  - 10.3.5.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.5.1. Brazil
  - 10.4.5.2. Argentina
  - 10.4.5.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.5.1. China
  - 10.5.5.2. India
  - 10.5.5.3. Japan
  - 10.5.5.4. South Korea
  - 10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. F. Hoffmann-La Roche Ltd
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Thermo Fisher Scientific Inc.
12.3. Abbott
12.4. Merck KGaA
12.5. Randox Laboratories Ltd.
12.6. SEKISUI Diagnostics
12.7. Abcam Limited.
12.8. Diazyme Laboratories, Inc.
12.9. Cell Biolabs, Inc.
12.10. DiaSys Diagnostic Systems GmbH (LIST NOT EXHAUSTIVE)